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M
alignant tertian” and “benign 
tertian” are terms that have 
long been used for two of the 
major diseases we recognise as malaria. 
The former is generally considered 
to be synonymous with Plasmodium 
falciparum and the latter with P. vivax 
infection. As the names “malignant” 
and “benign” suggest, the current 
dogma is that P. falciparum can be 
severe and life-threatening while P. 
vivax tends to be mild. However, two 
studies published in this issue of PLoS 
Medicine challenge this dogma. 
The Two New Studies
Ric Price and colleagues, in a 
prospective study based in Timika, 
southern Papua in Indonesia [1], 
and Blaise Genton and colleagues, 
in a prospective study in the Wosera 
region of Papua New Guinea [2], 
report similar rates and outcomes 
of severe malaria due to P. vivax or 
P. falciparum. The two studies had 
different settings, and the cultural and 
ethnic characteristics of the patient 
populations were also different. Price 
and colleagues collected data from 
all patients attending the outpatient 
and inpatient departments of the only 
hospital in the region, using systematic 
data forms and computerised hospital 
records. In contrast, Genton and 
colleagues investigated patients 
presenting at two rural health facilities.
In both settings, clinical and 
severe disease was most common in 
young children, with P. vivax cases 
peaking at an earlier age than those 
of P. falciparum. In Timika, in children 
under five years old, around 30% of 
cases of either P. falciparum or P. vivax 
were classed as severe, and around 
80% of such cases were accompanied 
by severe anaemia (haemoglobin less 
than 5 g/dl). The remainder presented 
with respiratory distress, impaired 
consciousness (i.e., cerebral malaria), 
or overlapping syndromes. In the 
Wosera, in children under five years 
attending the health centre, around 
9% of vivax and 12% of falciparum 
infections were classified as severe 
malaria. However, respiratory distress 
was defined less stringently in the 
Wosera (more than 40 breaths/minute 
from two to 60 months) than in Timika 
(more than 50 breaths/minute in 
this age group). When cough and 
diarrhoea (which are poorly specific 
for malaria) were used as exclusions 
in the Wosera study, severe malaria 
rates in children under five years fell 
to 7% and 4% of P. falciparum and P. 
vivax infections, respectively. In the 
Wosera, anaemia occurred in about 
20% and 40% of severe cases of vivax 
and falciparum, respectively, while 
respiratory distress occurred in 60% 
and 40% of severe cases of vivax and 
falciparum, respectively. Neurologic 
symptoms were present in 25% of 
severe cases of either species. 
The cases of cerebral malaria 
due to P. vivax reported in both 
studies, occurring in all age groups, 
are intriguing, because this malaria 
complication has rarely been reported 
previously in association with P. vivax 
infection. In P. falciparum, cerebral 
malaria is primarily attributed to 
sequestration of infected erythrocytes 
in cerebral vessels. As P. vivax does not 
sequester, coma must arise by other 
means—perhaps of systemic metabolic 
origin—in vivax malaria. This aetiology 
may also underlie some cerebral 
malaria presentations in children.
Both studies, inevitably, have 
limitations. First, co-morbidities, 
including concomitant bacterial or 
viral infections, which could have 
decreased the malaria-attributable 
fraction of disease [3], were not actively 
investigated. Second, microscopy 
was used for parasite detection and 
speciation, which routinely leads to 
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Linked Research Articles
This Research in Translation discusses 
the following new studies published in 
PLoS Medicine:
Genton B, D’Acremont V, Rare L, Baea K, 
Reeder JC, et al. (2008) Plasmodium vivax 
and mixed infections are associated with 
severe malaria in children: A prospective 
cohort study from Papua New Guinea. 
PLoS Med 5(6): e127. doi:10.1371/journal.
pmed.0050127
In a study carried out in Papua New 
Guinea, Blaise Genton and colleagues 
show that Plasmodium vivax is associated 
with severe malaria.
Tjitra E, Anstey NM, Sugiarto P, 
Warikar N, Kenangalem E, et al. (2008) 
Multidrug-resistant Plasmodium vivax 
associated with severe and fatal malaria: 
A prospective study in Papua, Indonesia. 
PLoS Med 5(6): e128. doi:10.1371/journal.
pmed.0050128
Ric Price and colleagues present 
data from southern Papua, Indonesia, 
suggesting that malaria resulting from 
infection with Plasmodium vivax is 
associated with substantial morbidity and 
mortality.
Research in Translation discusses health interventions 
in the context of translation from basic to clinical 
research, or from clinical evidence to practice.PLoS Medicine  |  www.plosmedicine.org 0876 June 2008  |  Volume 5  |  Issue 6  |  e136
marked underestimation of mixed 
infections in particular [4]. Some 
“severe vivax” cases may actually have 
been mixed infections. 
Severe Vivax Malaria
Despite these limitations, a striking 
feature of the two studies is the overall 
comparable incidence of severe 
disease in P. vivax and P. falciparum 
infections in each setting. There 
were differences in the prevalence 
of the components of severe disease 
in the two locations and a notable 
disparity in the overall rates of severe 
disease. Thus, in Timika, anaemia 
defined severe malaria more often 
than in Wosera, where anaemia was 
especially infrequent in severe vivax. 
This difference may be attributable 
to the fact that in Timika, both 
P. vivax and P. falciparum were 
commonly resistant to chloroquine, 
the first-line malaria treatment (with 
sulfadoxine–pyrimethamine in the 
case of P. falciparum), for much of 
the study period. Because persistent 
blood infections with malaria are likely 
to increase anaemia, drug treatment 
failure could have contributed to 
the high anaemia rates in Timika. In 
Wosera, where chloroquine resistance 
is common in P. falciparum but rare 
in P. vivax, severe anaemia defined 
40% of severe falciparum cases, but 
only 20% of severe vivax cases. Thus 
the Wosera data are also consistent 
with parasite drug resistance as a 
factor in anaemia. If these conjectures 
are correct, the recent adoption of 
dihydroartemisinin–piperaquine 
treatment in Papua [5] may lead to a 
significant decrease in severe malarial 
anaemia. 
Other factors, such as host 
genetics, could also have influenced 
the differences in severe disease 
manifestation between study sites. It 
has been shown, for example, that 
children in Papua New Guinea with 
the red cell genetic polymorphism 
“South East Asian ovalocytosis”, a trait 
common in this population, are almost 
completely protected from cerebral 
malaria [6]. In Timika, indigenous 
Papuans were much more likely to be 
severely anaemic than were immigrants. 
Might host genetics have contributed to 
the high anaemia rates reported in the 
Timika study? 
Interactions between Vivax and 
Falciparum
There is a view that malarial disease 
severity in New Guinea may be lower 
overall than in Africa. For example, 
case fatality rates for P. falciparum 
among hospitalised children in New 
Guinea ranged from 1.6% to 3.5% 
[7,8] versus 2% to 9% in recent African 
studies [9–11]. This difference raises 
the question of whether P. vivax, which 
is common in New Guinea but rare 
in Africa, may actually ameliorate the 
severity of P. falciparum where the two 
species are co-endemic. 
Maitland and colleagues have 
suggested that the earlier age peak for 
P. vivax disease may protect against the 
later-acquired P. falciparum through 
species-transcending immunity [12]. 
Studies have shown that symptoms of 
P. vivax or P. falciparum infection are, 
indeed, significantly reduced by recent 
previous P. vivax infection (but not P. 
falciparum infection) [13]. In contrast, 
the two new studies in PLoS Medicine 
report that mixed species infections 
had worse outcomes than infections of 
either species alone [1,2]. If previous 
vivax infection does protect against 
severe P. falciparum infection, further 
investigations are needed so that 
policies for P. vivax control can balance 
reduction in severe vivax with possible 
loss of vivax-associated protection 
against severe P. falciparum infection. 
Malaria Severity Depends on 
Context
The findings of the two new studies 
[1,2] should be considered from 
a wider biological and historical 
perspective, which shows that malarial 
disease severity is highly context 
dependent. For example, from the 16th 
through the 19th centuries in England, 
mortality rates associated with “marsh 
agues”—probably due largely to vivax 
malaria—gradually fell from high to 
negligible levels. This fall occurred 
either because of attenuation of P. 
vivax infection through adaptation 
of parasite and/or host, or through 
environmental change, such as reduced 
exposure to other diseases or improved 
nutrition [14]. Indeed, host under-
nutrition and co-infections, including 
HIV, helminth, and acute bacterial 
or viral infections, can all influence 
the outcomes in malaria [3]. Access 
Box 1. Crucial Tools for P. vivax 
Control
sÈ %FFECTIVEÈFIRST
LINEÈTREATMENT 
Artemisinin-based combination 
therapies are generally effective, but 
longer-acting combinations may 
additionally prevent early relapses.
sÈ (IGHLYÈSENSITIVEÈRAPIDÈDIAGNOSTICÈ
tests. Present tests are inadequately 
sensitive at low parasitaemia, which is 
common in P. vivax.
sÈ 0REVENTIVEÈTHERAPY The role of 
intermittent preventive treatment in 
pregnancy or childhood against vivax 
is unknown. Small studies suggest 
that insecticide-treated bed nets 
decrease disease. 
sÈ 3AFEÈDRUGSÈFORÈELIMINATIONÈOFÈLIVERÈ
stages. G6PD deficiency, selected 
for by malaria, can result in fatal 
haemolysis from current agents.
sÈ 6ACCINATIONÈNew vaccines are 
entering human trials. If efficacious, 
their deployment will require major 
planning efforts.
&IVEÈ+EYÈ0APERSÈINÈTHEÈ&IELD
Grimberg et al., 2007 [19]  
The investigators show that antibodies 
directed against “region two” of PvDBP 
inhibit merozoite invasion, suggesting 
that vaccines targeted towards this 
region could reduce blood stage 
infection. 
Barcus et al., 2007 [7]  
Along with the two new papers in this 
issue of PLoS Medicine [1,2], Barcus and 
colleagues’ study contributes to our 
understanding of the importance of P. 
vivax as a cause of severe clinical disease. 
0ANICHAKULÈETÈALÈÈ;= 
This paper represents a significant 
advance in the difficult process of 
developing robust in vitro culture 
systems for P. vivax. 
Ratcliff et al., 2007 [5]  
Both treatments cured falciparum 
and vivax malaria with high efficacy, 
but dihydroartemisinin–piperaquine 
was much better than artemether–
lumefantrine at preventing re-infections 
with P. falciparum and relapses of P. vivax 
during a six-week follow-up.
Singh et al., 2006 [18]  
This paper shows how the Duffy binding 
protein interacts with its ligand, which is 
also relevant to understanding structure 
and interactions of other important 
adhesive proteins of malaria parasites.PLoS Medicine  |  www.plosmedicine.org 0877 June 2008  |  Volume 5  |  Issue 6  |  e136
to antimalarial drugs and presence of 
parasite drug resistance are clearly also 
relevant to the clinical outcome. 
P. vivax infection is characterised by 
relapse in which dormant liver stages 
awaken, initiating new bouts of blood 
infection. Repeated malarial blood 
infections, from whatever source, have 
debilitating consequences including 
cachexia, spontaneous abortions, male 
infertility, developmental arrest, and 
impaired mental function [15]. All of 
these debilitating clinical features have 
been present in populations where 
P. vivax is known, or presumed, to 
have been the main prevalent malaria. 
However, these manifestations are 
also context dependent—they are 
influenced by circumstances such as 
the level of endemicity, existence of 
co-infections, access to treatment, and 
presence of parasite resistance. 
It is interesting that the present 
reports of severe vivax malaria come 
from New Guinea, where drug-
resistant P. vivax was first reported. 
This drug resistance itself could be 
a driver of severity together with the 
particularly high regional malaria 
transmission force. Were severe vivax 
to be found more widely, it would have 
significant implications for control 
of the infection, especially as P. vivax 
invariably increases relative to P. 
falciparum under effective transmission 
reduction [16]. 
The Way Forward for Vivax Malaria 
Control
With calls for increased efforts to 
control malaria internationally, it will 
be important to ensure that P. vivax 
receives appropriate attention. We 
still lack reliable estimates of its global 
burden, and are only now starting to 
appreciate certain aspects of disease 
presentation of P. vivax malarial 
infection. The burden and severity 
of vivax in different settings requires 
further study. With the availability 
of the P. vivax genome (GenBank 
accession no. AAKM00000000), 
it will be possible to compare 
isolates associated with severe or 
uncomplicated disease. However, 
connecting genetic differences with 
pathogenic potential may not be 
straightforward [17]. 
Better disease control (see Box 1) 
might include preventive strategies 
(vaccines, insecticide-treated bed nets, 
and intermittent preventive treatment), 
more effective curative treatment 
(finding the most suitable alternative 
to chloroquine), and better relapse 
prevention (long-acting drugs such 
as dihydroartemisinin–piperaquine 
decrease early relapse compared to 
other artemisinin-based combination 
therapies [5]). Elimination of dormant 
parasites in the liver (hypnozoites) is 
especially difficult because available 
drugs can cause severe haemolysis in 
individuals with glucose-6-phosphate 
dehydrogenase (G6PD) deficiency. A 
simple point-of-care assay for G6PD 
deficiency, or new, safer drugs that 
target liver stage parasites, would be 
invaluable tools for eradication of 
hypnozoites. 
Vaccines against P. vivax are in 
development. One target is the P. 
vivax Duffy binding protein (PvDBP), 
which mediates merozoite invasion of 
erythrocytes [18, 19]; human vaccine 
studies using this target are likely 
to begin this year. Another target is 
the P. vivax gamete surface protein 
Pvs25, a candidate for a transmission-
blocking vaccine. Indeed, this vaccine 
candidate is already in Phase I human 
trials [20]. Should either candidate 
progress to large-scale trials, it will be 
critical to examine impact on both P. 
vivax infection (including, potentially, 
increased chronicity of infection and 
anaemia following PvDBP vaccination) 
and P. falciparum infection. While 
New Guinea is an ideal site in which 
to evaluate such vaccines, evaluation 
must also be done in low-transmission 
areas where most P. vivax infections are 
symptomatic, and where diminished 
symptomatology could dangerously 
postpone treatment. The two reports 
by Price et al. and Genton et al. provide 
information about disease burden 
critical to improved decision making 
for the public health management of P. 
vivax malaria [1,2].  
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